Acumen develops targeted therapies for the safe and effective treatment of Alzheimer’s disease and related neurodegenerative diseases. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the cusp of realizing the therapeutic potential of Aβo targeted drugs. Acumen and Merck & Co., through an eight-year research collaboration, produced our lead drug candidate, ACU193, for which Acumen holds exclusive rights. Extensive preclinical research at Merck demonstrates ACU193 selectively targets Aβo with a favorable safety profile and efficacy. Under the Acumen team’s stewardship, we further continued to profile in vivo efficacy and developability of ACU193. In 2017, the National Institute of Aging awarded a competitive $3.6 million U01 grant for preclinical and early clinical development of ACU193.

Acumen Pharmaceuticals Inc

Acumen develops targeted therapies for the safe and effective treatment of Alzheimer’s disease and related neurodegenerative diseases. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the cusp of realizing the therapeutic potential of Aβo targeted drugs.

Should you buy, sell, or hold Acumen Pharmaceuticals Inc (ABOS) ?

Acumen Pharmaceuticals Inc (ABOS) : Buy or Sell